Colorectal cancer prognosis: is it all mutation, mutation, mutation?
For the 500,000 new cases of colorectal cancer in the world each year, identification of patients with a worse prognosis and those who are more likely to respond to treatment is a challenge. There is an increasing body of evidence correlating genetic mutations with outcome in tumours derived from human colorectal cancer cohorts. K-ras, but not p53 or APC, mutations appear to be associated with poorer overall survival in colorectal cancer patients.
Hassan
A B
AB
Department of Cellular and Molecular Medicine (formerly Pathology and Microbiology), School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK. Bass.Hassan@Bristol.ac.uk
Paraskeva
C
C
D000368:Aged; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D017491:Genes, APC; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D015996:Survival Rate
D004273:DNA, Neoplasm